The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Abstract
Thirty-four normocalcaemic women with multiple osteolytic bone metastases from breast cancer were randomly allocated to treatment with disodium dichloromethylene diphosphonate (Cl2MDP) 1600 mg/day orally (17) or placebo (17) for 3-9 months. Fasting urinary hydroxyproline/creatinine and calcium/creatinine ratios declined in the Cl2MDP group but not in the placebo group. Four patients in the placebo group died from hypercalcaemia. New bone metastases were more common in patients on placebo and these patients also required more analgesic drugs than those on Cl2MDP. Cl2MDP seemed to reduce bone pain and bone resorption and prevent the development of hypercalcaemia caused by osteolytic metastases. The formation of new bone metastases and the growth of old ones seemed to be retarded by Cl2MDP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 1983 the bisphosphonate clodronate was shown to reduce hypercalcemia, bone pain, and osteolytic progression in breast cancer patients with bone metastases (306).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [306]
Citations
Cites
Albumin standards and the measurement of serum albumin with bromcresol green
Doumas, B. T., Ard Watson, W., & Biggs, H. G. (1971) · Clinica Chimica Acta · doi:10.1016/0009-8981(71)90365-2 · Cited by 3,062
Albumin standards and the measurement of serum albumin with bromcresol green
Doumas, B. T., Ard Watson, W., & Biggs, H. G. (1997) · Clinica Chimica Acta · doi:10.1016/s0009-8981(96)06447-9 · Cited by 2,767
Modifications of a specific assay for hydroxyproline in urine
Kivirikko, K. I., Laitinen, O., & Prockop, D. J. (1967) · Analytical Biochemistry · doi:10.1016/0003-2697(67)90160-1 · Cited by 1,086
Evidence for the Secretion of an Osteoclast Stimulating Factor in Myeloma
Mundy, G. R., Raisz, L. G., Cooper, R. A., Schechter, G. P., & Salmon, S. E. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411142912001 · Cited by 671
Mechanisms of bone destruction in the development of skeletal metastases
GALASKO, C. S. B. (1976) · Nature · doi:10.1038/263507a0 · Cited by 272
Direct resorption of bone by human breast cancer cells in vitro
EILON, G., & MUNDY, G. R. (1978) · Nature · doi:10.1038/276726a0 · Cited by 235
Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple Myeloma
Siris, E. S., Sherman, W. H., Baquiran, D. C., Schlatterer, J. P., Osserman, E. F., & Canfield, R. E. (1980) · New England Journal of Medicine · doi:10.1056/nejm198002073020602 · Cited by 185
Douglas, D., Graham G, R., Preston, C., Prenton, M., Duckworth, T., Kanis, J., Eric Preston, F., & Stuart Woodhead, J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91496-8 · Cited by 177
INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)
Van Breukelen, F. J. M., Bijvoet, O., & Van Oosterom, A. T. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91319-9 · Cited by 173
The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture
Fast, D. K., Felix, R., Dowse, C. M., Neuman, W. F., & Fleisch, H. A. (1978) · Biochemical Journal · doi:10.1042/bj1720097 · Cited by 150
Cited by
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Fleisch, H. (1991) · Drugs · doi:10.2165/00003495-199142060-00003 · Cited by 581
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Metadata
- Authors
- Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento, A.-L., Selander, K., Lamberg-Allardt, C., & Holmström, T.
- Affiliations
- University of Helsinki (FI)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1983-01
- Volume
- 321
- Issue
- 8317
- Pages
- 146-149
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1965682822
- Cited by
- 209
- References
- 24
- Citations by year
- 2020: 3 · 2019: 2 · 2017: 2 · 2016: 2 · 2013: 2 · 2012: 2
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, osteolytic bone metastasis, breast cancer, hypercalcemia, bone resorption, urinary hydroxyproline, bone pain, analgesic requirement
- MeSH terms
- Adult, Aged, Analgesics, Antineoplastic Agents, Bone Neoplasms, Bone Resorption, Breast Neoplasms, Clinical Trials as Topic, Clodronic Acid, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hydrocarbons, Chlorinated, Methylene Chloride, Middle Aged, Osteolysis, Random Allocation, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. https://app.cochat.ai/papers/10.1016/s0140-6736(83)92755-1
- The paper
- Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento, A.-L., Selander, K., Lamberg-Allardt, C., & Holmström, T. (1983). Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. The Lancet. https://doi.org/10.1016/s0140-6736(83)92755-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.